(2023). Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis.
Chicago Style (17th ed.) CitationPhosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis. 2023.
MLA (8th ed.) CitationPhosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis. 2023.
Warning: These citations may not always be 100% accurate.
